Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Orum Therapeutics
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
October 14, 2025
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
October 02, 2024
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
July 16, 2024
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022
December 10, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Announces Presentation at ASH 2022 Annual Meeting
November 03, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors
October 31, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics to Participate at Investor Conferences in September
September 06, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
April 08, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Announces Formation of Scientific Advisory Board
April 04, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Appoints David Main to Board of Directors
March 23, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics to Participate in February Investor Conferences
February 10, 2022
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Appoints Olaf Christensen, M.D., as Chief Medical Officer
October 06, 2021
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
June 23, 2021
From
Orum Therapeutics
Via
Business Wire
Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer
May 26, 2021
From
Orum Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Starting at $3.75
/
week.
Subscribe Today